Metastatic bone disease: Role of transcription factors and future targets

Bone

Volumn 48, Issue 1, 2011, Pages 30-36

  Pratap, Jitesh ^a   Lian, Jane B ^b   Stein, Gary S ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Breast and prostate tumors in bone; MicroRNA; Osteolytic disease; Runx AML Cbfa1 factors; Runx2; Smads; Subnuclear targeting

Indexed keywords

ANGIOPOIETIN; COLONY STIMULATING FACTOR 1; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2; EPIREGULIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MICRORNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN BCL 2; TRANSCRIPTION FACTOR RUNX; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR RUNX3; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CELL MIGRATION; CELL SURVIVAL; CELL TRANSFORMATION; DISTANT METASTASIS; DRUG TARGETING; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; METASTASIS INHIBITION; METASTASIS POTENTIAL; NONHUMAN; POINT MUTATION; PROGNOSIS; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN INDUCTION; REVIEW; RNA INTERFERENCE; TISSUE SPECIFICITY; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR MICROENVIRONMENT;

EID: 78650307699     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.05.035     Document Type: Review

References (95)

1. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
2. Creighton C.J., Chang J.C., Rosen J.M. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 2010, 15:253-260.
3. Young D.W., Hassan M.Q., Pratap J., Galindo M., Zaidi S.K., Lee S.H., et al. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 2007, 445:442-446.
4. Ali S.A., Zaidi S.K., Dacwag C.S., Salma N., Young D.W., Shakoori A.R., et al. Phenotypic transcription factors epigenetically mediate cell growth control. Proc Natl Acad Sci U S A 2008, 105:6632-6637.
5. Bakshi R., Zaidi S.K., Pande S., Hassan M.Q., Young D.W., Montecino M., et al. The leukemogenic t(8;21) fusion protein AML1-ETO controls ribosomal RNA genes and associates with nucleaolar organizing regions at mitotic chromosomes. J Cell Sci 2008, 21:3981-3990.
6. Blyth K., Cameron E.R., Neil J.C. The runx genes: gain or loss of function in cancer. Nat Rev Cancer 2005, 5:376-387.
7. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 2004, 23:4284-4296.
8. Chuang L.S., Ito Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 2010, 29:2605-2615.
9. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
10. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771.
11. Choi J.-Y., Pratap J., Javed A., Zaidi S.K., Xing L., Balint E., et al. Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development. Proc Natl Acad Sci U S A 2001, 98:8650-8655.
12. Thomas D.M., Johnson S.A., Sims N.A., Trivett M.K., Slavin J.L., Rubin B.P., et al. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 2004, 167:925-934.
13. Nathan S.S., Pereira B.P., Zhou Y.F., Gupta A., Dombrowski C., Soong R., et al. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep 2009, 36:153-158.
14. Barnes G.L., Hebert K.E., Kamal M., Javed A., Einhorn T.A., Lian J.B., et al. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases associated osteolytic disease. Cancer Res 2004, 64:4506-4513.
15. Javed A., Barnes G.L., Pratap J., Antkowiak T., Gerstenfeld L.C., van Wijnen A.J., et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci U S A 2005, 102:1454-1459.
16. Pratap J., Imbalzano K., Underwood J., Cohet N., Gokul K.D., Akech J., et al. Ectopic Runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression. Cancer Res 2009, 69:6807-6814.
17. Pratap J., Lian J.B., Javed A., Barnes G.L., van Wijnen A.J., Stein J.L., et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006, 25:589-600.
18. Casimiro S., Guise T.A., Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009, 310:71-81.
19. Zaidi S.K., Pande S., Pratap J., Gaur T., Grigoriu S., Ali S.A., et al. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci U S A 2007, 104:19861-19866.
20. Zaidi S.K., Young D.W., Javed A., Pratap J., Montecino M., van Wijnen A., et al. Nuclear microenvironments in biological control and cancer. Nat Rev Cancer 2007, 7:454-463.
21. Pratap J., Galindo M., Zaidi S.K., Vradii D., Bhat B.M., Robinson J.A., et al. Cell growth regulatory role of Runx2 during proliferative expansion of pre-osteoblasts. Cancer Res 2003, 63:5357-5362.
22. Lian J.B., Balint E., Javed A., Drissi H., Vitti R., Quinlan E.J., et al. Runx1/AML1 hematopoietic transcription factor contributes to skeletal development in vivo. J Cell Physiol 2003, 196:301-311.
23. Smith N., Dong Y., Lian J.B., Pratap J., Kingsley P.D., van Wijnen A.J., et al. Overlapping expression of Runx1(Cbfa2) and Runx2(Cbfa1) transcription factors supports cooperative induction of skeletal development. J Cell Physiol 2005, 203:133-143.
24. Debnath J., Brugge J.S. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005, 5:675-688.
25. Bissell M.J., Weaver V.M., Lelievre S.A., Wang F., Petersen O.W., Schmeichel K.L. Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res 1999, 59:1757s-1763s.
26. Inman C.K., Li N., Shore P. Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein. Mol Cell Biol 2005, 25:3182-3193.
27. Das K., Leong D.T., Gupta A., Shen L., Putti T., Stein G.S., et al. Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur J Cancer 2009, 45:2239-2248.
28. Lim M., Zhong C., Yang S., Bell A.M., Cohen M.B., Roy-Burman P. Runx2 regulates survivin expression in prostate cancer cells. Lab Invest 2010, 90:222-233.
29. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70.
30. Morrissey C., Brown L.G., Pitts T.E., Vessella R.L., Corey E. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia 2010, 12:192-205.
31. Yang S., Lim M., Pham L.K., Kendall S.E., Reddi A.H., Altieri D.C., et al. Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways. Cancer Res 2006, 66:4285-4290.
32. Alarmo E.L., Parssinen J., Ketolainen J.M., Savinainen K., Karhu R., Kallioniemi A. BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Lett 2009, 275:35-43.
33. Lin D.L., Tarnowski C.P., Zhang J., Dai J., Rohn E., Patel A.H., et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001, 47:212-221.
34. Javed A., Bae J.S., Afzal F., Gutierrez S., Pratap J., Zaidi S.K., et al. Structural coupling of Smad and Runx2 for execution of the BMP2 osteogenic signal. J Biol Chem 2008, 283:8412-8422.
35. Bellahcene A., Castronovo V., Ogbureke K.U., Fisher L.W., Fedarko N.S. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008, 8:212-226.
36. Zelzer E., Glotzer D.J., Hartmann C., Thomas D., Fukai N., Soker S., et al. Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev 2001, 106:97-106.
37. Ji C., Casinghino S., Chang D.J., Chen Y., Javed A., Ito Y., et al. CBFa(AML/PEBP2)-related elements in the TGF-beta type I receptor promoter and expression with osteoblast differentiation. J Cell Biochem 1998, 69:353-363.
38. Nannuru K.C., Futakuchi M., Varney M.L., Vincent T.M., Marcusson E.G., Singh R.K. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res 2010, 70:3494-3504.
39. Pratap J., Javed A., Languino L.R., van Wijnen A.J., Stein J.L., Stein G.S., et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005, 25:8581-8591.
40. Franceschi R.T., Xiao G., Jiang D., Gopalakrishnan R., Yang S., Reith E. Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation. Connect Tissue Res 2003, 44(Suppl 1):109-116.
41. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
42. Clezardin P. Integrins in bone metastasis formation and potential therapeutic implications. Curr Cancer Drug Targets 2009, 9:801-806.
43. Pratap J., Wixted J.J., Gaur T., Zaidi S.K., Dobson J., Gokul K.D., et al. Runx2 transcriptional activation of Indian hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 2008, 68:7795-7802.
44. Akech J., Wixted J.J., Bedard K., van der Deen M., Hussain S., Guise T.A., et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010, 29:811-821.
45. Clines G.A., Guise T.A. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008, 10:e7.
46. Sterling J.A., Oyajobi B.O., Grubbs B., Padalecki S.S., Munoz S.A., Gupta A., et al. The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res 2006, 66:7548-7553.
47. Roudier M.P., Morrissey C., True L.D., Higano C.S., Vessella R.L., Ott S.M. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 2008, 180:1154-1160.
48. Brubaker K.D., Vessella R.L., Brown L.G., Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003, 56:13-22.
49. van der Deen M., Akech J., Wang T., FitzGerald T.J., Altieri D.C., Languino L.R., et al. The cancer-related Runx2 protein enhances cell growth and responses to andogen and TGFβ in prostate cancer cells. J Cell Biochem 2010, 109:828-837.
50. Robinson D.R., Zylstra C.R., Williams B.O. Wnt signaling and prostate cancer. Curr Drug Targets 2008, 9:571-580.
51. Emami K.H., Corey E. When prostate cancer meets bone: control by wnts. Cancer Lett 2007, 253:170-179.
52. Hall C.L., Keller E.T. The role of Wnts in bone metastases. Cancer Metastasis Rev 2006, 25:551-558.
53. Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010, 223:14-26.
54. Zaidi S.K., Sullivan A.J., Medina R., Ito Y., van Wijnen A.J., Stein J.L., et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 2004, 23:790-799.
55. Rabbani S.A., Valentino M.L., Arakelian A., Ali S., Boschelli F. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther 2010, 9:1147-1157.
56. Araujo J., Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 2010, Electronic publication ahead of print.
57. Saad F., Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010, 36:177-184.
58. Pouliot F., Blais A., Labrie C. Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res 2003, 63:277-281.
59. Miyazono K., Maeda S., Imamura T. Coordinate regulation of cell growth and differentiation by TGF-beta superfamily and Runx proteins. Oncogene 2004, 23:4232-4237.
60. Ford A.M., Palmi C., Bueno C., Hong D., Cardus P., Knight D., et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest 2009, 119:826-836.
61. Ito Y., Miyazono K. RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev 2003, 13:43-47.
62. Lee K.S., Hong S.H., Bae S.C. Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene 2002, 21:7156-7163.
63. Gaur T., Lengner C.J., Hovhannisyan H., Bhat R.A., Bodine P.V.N., Komm B.S., et al. Canonical WNT signaling promotes osteogenesis by directly stimulating RUNX2 gene expression. J Biol Chem 2005, 280:33132-33140.
64. Kahler R.A., Galindo M., Lian J., Stein G.S., van Wijnen A.J., Westendorf J.J. Lymphocyte enhancer-binding factor 1 (Lef1) inhibits terminal differentiation of osteoblasts. J Cell Biochem 2006, 97:969-983.
65. Li Z.G., Yang J., Vazquez E.S., Rose D., Vakar-Lopez F., Mathew P., et al. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 2008, 27:596-603.
66. Yang J., Fizazi K., Peleg S., Sikes C.R., Raymond A.K., Jamal N., et al. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 2001, 61:5652-5659.
67. Dai J., Hall C.L., Escara-Wilke J., Mizokami A., Keller J.M., Keller E.T. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res 2008, 68:5785-5794.
68. Bu G., Lu W., Liu C.C., Selander K., Yoneda T., Hall C., et al. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer 2008, 123:1034-1042.
69. Baniwal S.K., Khalid O., Sir D., Buchanan G., Coetzee G.A., Frenkel B. Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol 2009, 23:1203-1214.
70. Liu X.H., Kirschenbaum A., Yao S., Liu G., Aaronson S.A., Levine A.C. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Cancer Res 2007, 67:5747-5753.
71. Fowler M., Borazanci E., McGhee L., Pylant S.W., Williams B.J., Glass J., et al. RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem 2006, 97:1-17.
72. Khalid O., Baniwal S.K., Purcell D.J., Leclerc N., Gabet Y., Stallcup M.R., et al. Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer. Endocrinology 2008, 149:5984-5995.
73. Hassan M.Q., Saini S., Gordon J.A., van Wijnen A.J., Montecino M., Stein J.L., et al. Molecular switches involving homeodomain proteins, HOXA10 and RUNX2 regulate osteoblastogenesis. Cells Tissues Organs 2009, 189:122-125.
74. Hassan M.Q., Tare R.S., Lee S., Mandeville M., Morasso M.I., Javed A., et al. BMP2 commitment to the osteogenic lineage involves activation of Runx2 by Dlx3 and a homeodomain transcriptional network. J Biol Chem 2006, 281:40515-40526.
75. Hassan M.Q., Tare R., Lee S.H., Mandeville M., Weiner B., Montecino M., et al. HOXA10 controls osteoblastogenesis by directly activating bone regulatory and phenotypic genes. Mol Cell Biol 2007, 27:3337-3352.
76. Gordon J.A., Hassan M.Q., Saini S., Montecino M., van Wijnen A.J., Stein G.S., et al. Pbx1 represses osteoblastogenesis by blocking Hoxa10-mediated recruitment of chromatin remodeling factors. Mol Cell Biol 2010, Electronic publication ahead of print.
77. Barnes G.L., Javed A., Waller S.M., Kamal M.H., Hebert K.E., Hassan M.Q., et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003, 63:2631-2637.
78. Ruhin-Poncet B., Ghoul-Mazgar S., Hotton D., Capron F., Jaafoura M.H., Goubin G., et al. Msx and dlx homeogene expression in epithelial odontogenic tumors. J Histochem Cytochem 2009, 57:69-78.
79. Wang H., Lindsey S., Konieczna I., Bei L., Horvath E., Huang W., et al. Constitutively active SHP2 cooperates with HoxA10 overexpression to induce acute myeloid leukemia. J Biol Chem 2009, 284:2549-2567.
80. Ko S.Y., Lengyel E., Naora H. The Mullerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions. Mol Cell Endocrinol 2010, 317:112-119.
81. Han H.J., Russo J., Kohwi Y., Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008, 452:187-193.
82. Westendorf J.J. Histone deacetylases in control of skeletogenesis. J Cell Biochem 2007, 102:332-340.
83. Schroeder T.M., Westendorf J.J. Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 2005, 20:2254-2263.
84. Kim H.N., Ha H., Lee J.H., Jung K., Yang D., Woo K.M., et al. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. Eur J Pharmacol 2009, 623:22-29.
85. Grabiec A.M., Krausz S., de Jager W., Burakowski T., Groot D., Sanders M.E., et al. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 2010, 184:2718-2728.
86. Ma X., Ezzeldin H.H., Diasio R.B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009, 69:1911-1934.
87. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714.
88. Ma L., Reinhardt F., Pan E., Soutschek J., Bhat B., Marcusson E.G., et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010, 28:341-347.
89. Takeshita F., Patrawala L., Osaki M., Takahashi R.U., Yamamoto Y., Kosaka N., et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 2010, 18:181-187.
90. Valastyan S., Reinhardt F., Benaich N., Calogrias D., Szasz A.M., Wang Z.C., et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009, 137:1032-1046.
91. Korpal M., Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008, 5:115-119.
92. Khew-Goodall Y., Goodall G.J. Myc-modulated miR-9 makes more metastases. Nat Cell Biol 2010, 12:209-211.
93. Zaidi S.K., Dowdy C.R., van Wijnen A.J., Lian J.B., Raza A., Stein J.L., et al. Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network. Cancer Res 2009, 69:8249-8255.
94. Li Z., Hassan M.Q., Volinia S., van Wijnen A.J., Stein J.L., Croce C.M., et al. A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc Natl Acad Sci U S A 2008, 105:13906-13911.
95. Huang J., Zhao L., Xing L., Chen D. MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem Cells 2010, 28:357-364.